Game-changing obesity drugs go mainstream

Mariana Lenharo in Nature:

A new generation of drugs is revolutionizing the treatment of obesity and astonishing researchers with their potency. The drug semaglutide, for example, enabled one-third of clinical-trial participants to shed at least 20% of their body weight1. Tirzepatide, a competing therapy, achieved similar results in more than half of study participants2.

Despite their high effectiveness, researchers are learning that these drugs are not necessarily the solution for everyone living with obesity. “Everybody wants to try them but not everyone responds to them,” says Andres Acosta, an obesity specialist at Mayo Clinic in Rochester, Minnesota. Now that semaglutide and tirzepatide have been around for some time, health-care providers are beginning to identify who is likely to benefit the most from them — and to recognize challenges in the drugs’ use.

More here.